Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clomiphene citrate
Drug ID BADD_D00498
Description A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Indications and Usage Used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome) to induce ovulation.
Marketing Status approved; investigational
ATC Code G03GB02
DrugBank ID DB00882
KEGG ID D00962
MeSH ID D002996
PubChem ID 60974
TTD Drug ID D0I5WB
NDC Product Code 51927-0249; 73377-229; 49884-701; 50090-0678; 10577-916; 46014-1122; 51927-0056; 0713-0885; 73212-029; 63629-2165; 63629-5302; 63275-9964; 63629-9276; 48087-0025; 49169-1040; 51552-1580; 68071-2638; 73309-047; 50090-6500; 17369-817; 48087-0144; 62991-2702; 61919-375; 38779-0390; 43647-456; 71052-338; 90027-025
UNII 1B8447E7YI
Synonyms Clomiphene | Clomifene | Chloramiphene | Clomifen | Clomiphene Citrate | Citrate, Clomiphene | Clomiphene Hydrochloride | Hydrochloride, Clomiphene | Serophene | Gravosan | Klostilbegit | Clostilbegit | Clomid | Clomide | Dyneric
Chemical Information
Molecular Formula C32H36ClNO8
CAS Registry Number 50-41-9
SMILES CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O) O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Retinal haemorrhage24.07.05.003; 06.10.01.001--Not Available
Retinal vascular disorder06.10.01.002; 24.03.07.002--
Seizure17.12.03.001--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thyroid disorder05.02.01.002--Not Available
Thyroid neoplasm16.24.01.002; 05.02.05.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue neoplasm malignant stage unspecified16.13.07.003; 07.21.07.003--Not Available
Tracheo-oesophageal fistula22.04.07.003; 07.11.05.003; 03.16.02.002--Not Available
Trisomy 2103.20.01.002; 19.21.06.005; 17.03.07.005; 02.08.02.003--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Uterine haemorrhage24.07.03.004; 21.07.01.005--
Vasoconstriction24.04.03.008; 23.06.05.007--Not Available
Ventricular septal defect03.07.02.001; 02.04.02.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual acuity tests abnormal13.07.04.009--Not Available
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Vitreous detachment12.01.04.005; 06.09.01.002--Not Available
Vitreous floaters06.09.01.005--
Vomiting07.01.07.003--
Vulvovaginal dryness21.08.02.003--
Weight decreased13.15.01.005--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages